Zyversa Therapeutics Inc (ZVSA)

$0.63 -0.02 (-3.10%)
Market Cap 3.11M
Revenue (ttm) 0.00
Net Income (ttm) -9.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 179,000
Avg Vol 4,624,934
Day's Range N/A - N/A
Shares Out 4.77M
Stochastic %K 16%
Beta 0.74
Analysts Strong Buy
Price Target $12.00

Company Profile

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a...

Industry: Biotechnology
Sector: Healthcare
Phone: (754) 231-1688
Address:
2200 N. Commerce Parkway, Suite 208, Weston, United States
GreenResearchers
GreenResearchers Jun. 16 at 9:52 AM
GLMD is a powder keg ready to blow. Trading under cash with a $20+ book value, no debt, and a tiny float this isn’t just undervalued, it’s insanely mispriced. The chart is tightening, momentum is building, and massive GLP-1 obesity + fibrosis catalysts are around the corner. This sector has sent names flying 500%+… GLMD hasn’t even started. When the spark hits volume, PR, or smart money rotation this could rip like wildfire. One of the cleanest high-upside setups on the entire market right now. $ZVSA, $TNON, $SNPX, $OP
0 · Reply
rambo222
rambo222 Jun. 13 at 1:56 PM
$ZVSA The usual bs!
0 · Reply
John_D_Stockefeller
John_D_Stockefeller Jun. 12 at 9:09 PM
$ZVSA But we got more dilution……
0 · Reply
RollingDollars
RollingDollars Jun. 12 at 7:41 PM
$ZVSA
0 · Reply
Chucky91
Chucky91 Jun. 12 at 4:24 PM
$ZVSA we need more volume!!! $AYTU $BFRI
0 · Reply
rambo222
rambo222 Jun. 12 at 1:01 PM
$ZVSA As usual, mm fukery.
0 · Reply
GravyTrain1
GravyTrain1 Jun. 10 at 5:51 PM
$ZVSA looks primed for a pop!
0 · Reply
rambo222
rambo222 Jun. 10 at 3:16 PM
$ZVSA God forbid we go up more than .15 before the MMs and shorts sit on it. Fukrs.
0 · Reply
Chucky91
Chucky91 Jun. 10 at 3:12 PM
$ZVSA let's push this one $MLGO $MULN
0 · Reply
rayankhader
rayankhader Jun. 10 at 3:06 PM
$ZVSA sheeesh
0 · Reply
Latest News on ZVSA
ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's Diseases

May 20, 2025, 8:52 AM EDT - 27 days ago

ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's Diseases

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

May 12, 2025, 4:35 PM EDT - 5 weeks ago

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update

May 7, 2025, 7:57 AM EDT - 5 weeks ago

ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's Disease

Apr 29, 2025, 7:57 AM EDT - 6 weeks ago

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's Disease

ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development Status

Apr 24, 2025, 7:57 AM EDT - 7 weeks ago

ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development Status

ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)

Apr 8, 2025, 7:57 AM EDT - 2 months ago

ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)

ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 27, 2025, 9:15 AM EDT - 2 months ago

ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study

Mar 18, 2025, 7:57 AM EDT - 3 months ago

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model

Mar 12, 2025, 7:57 AM EDT - 3 months ago

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model

ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market

Mar 6, 2025, 8:00 AM EST - 3 months ago

ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market

ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes

Mar 5, 2025, 7:52 AM EST - 3 months ago

ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco

Dec 18, 2024, 7:55 AM EST - 6 months ago

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

Nov 20, 2024, 7:55 AM EST - 7 months ago

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

Nov 14, 2024, 8:10 AM EST - 7 months ago

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

Nov 5, 2024, 7:00 AM EST - 7 months ago

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs

Oct 29, 2024, 7:57 AM EDT - 8 months ago

ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

Oct 22, 2024, 7:57 AM EDT - 8 months ago

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

Oct 17, 2024, 7:50 AM EDT - 8 months ago

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

Oct 15, 2024, 7:50 AM EDT - 8 months ago

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

Oct 7, 2024, 7:55 AM EDT - 9 months ago

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

Aug 9, 2024, 4:40 PM EDT - 11 months ago

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

Aug 7, 2024, 7:50 AM EDT - 11 months ago

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

Jul 29, 2024, 7:45 AM EDT - 11 months ago

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

Jul 25, 2024, 7:57 AM EDT - 11 months ago

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model

Jul 18, 2024, 11:18 AM EDT - 11 months ago

ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C.

Jul 9, 2024, 7:57 AM EDT - 1 year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C.

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

May 15, 2024, 8:35 AM EDT - 1 year ago

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention

May 14, 2024, 7:57 AM EDT - 1 year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease

Apr 29, 2024, 7:57 AM EDT - 1 year ago

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

Apr 4, 2024, 7:57 AM EDT - 1 year ago

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 25, 2024, 8:17 AM EDT - 1 year ago

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease

Mar 18, 2024, 7:57 AM EDT - 1 year ago

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024

Mar 14, 2024, 7:57 AM EDT - 1 year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity

Feb 29, 2024, 7:57 AM EST - 1 year ago

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

Feb 28, 2024, 7:57 AM EST - 1 year ago

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

Feb 22, 2024, 7:47 AM EST - 1 year ago

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases

Feb 14, 2024, 7:53 AM EST - 1 year ago

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones

Feb 7, 2024, 8:02 AM EST - 1 year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

Jan 31, 2024, 7:57 AM EST - 1 year ago

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer's Disease

Jan 24, 2024, 7:57 AM EST - 1 year ago

ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer's Disease

ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis

Jan 17, 2024, 7:52 AM EST - 1 year ago

ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis

ZyVersa Therapeutics' CEO, Stephen C. Glover, Featured on Benzinga All Access

Jan 10, 2024, 8:06 AM EST - 1 year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover, Featured on Benzinga All Access

ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets

Jan 4, 2024, 7:50 AM EST - 1 year ago

ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024

Jan 3, 2024, 8:07 AM EST - 1 year ago

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P.

Dec 18, 2023, 8:12 AM EST - 1 year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P.

ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200

Dec 14, 2023, 7:01 AM EST - 1 year ago

ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200

ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes

Dec 7, 2023, 11:20 AM EST - 1 year ago

ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes

ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering

Dec 6, 2023, 9:00 PM EST - 1 year ago

ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering

ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100's Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways

Dec 6, 2023, 7:20 AM EST - 1 year ago

ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100's Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways

ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock

Nov 30, 2023, 11:30 AM EST - 1 year ago

ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock

GreenResearchers
GreenResearchers Jun. 16 at 9:52 AM
GLMD is a powder keg ready to blow. Trading under cash with a $20+ book value, no debt, and a tiny float this isn’t just undervalued, it’s insanely mispriced. The chart is tightening, momentum is building, and massive GLP-1 obesity + fibrosis catalysts are around the corner. This sector has sent names flying 500%+… GLMD hasn’t even started. When the spark hits volume, PR, or smart money rotation this could rip like wildfire. One of the cleanest high-upside setups on the entire market right now. $ZVSA, $TNON, $SNPX, $OP
0 · Reply
rambo222
rambo222 Jun. 13 at 1:56 PM
$ZVSA The usual bs!
0 · Reply
John_D_Stockefeller
John_D_Stockefeller Jun. 12 at 9:09 PM
$ZVSA But we got more dilution……
0 · Reply
RollingDollars
RollingDollars Jun. 12 at 7:41 PM
$ZVSA
0 · Reply
Chucky91
Chucky91 Jun. 12 at 4:24 PM
$ZVSA we need more volume!!! $AYTU $BFRI
0 · Reply
rambo222
rambo222 Jun. 12 at 1:01 PM
$ZVSA As usual, mm fukery.
0 · Reply
GravyTrain1
GravyTrain1 Jun. 10 at 5:51 PM
$ZVSA looks primed for a pop!
0 · Reply
rambo222
rambo222 Jun. 10 at 3:16 PM
$ZVSA God forbid we go up more than .15 before the MMs and shorts sit on it. Fukrs.
0 · Reply
Chucky91
Chucky91 Jun. 10 at 3:12 PM
$ZVSA let's push this one $MLGO $MULN
0 · Reply
rayankhader
rayankhader Jun. 10 at 3:06 PM
$ZVSA sheeesh
0 · Reply
rayankhader
rayankhader Jun. 10 at 2:36 PM
$ZVSA this will pay good patient
0 · Reply
RollingDollars
RollingDollars Jun. 10 at 2:31 PM
$ZVSA.
0 · Reply
Chucky91
Chucky91 Jun. 10 at 8:52 AM
$ZVSA
0 · Reply
Nizou
Nizou Jun. 9 at 1:38 PM
$ZVSA over 0.7 will fly
0 · Reply
petertradebull
petertradebull Jun. 7 at 10:09 AM
$ZVSA bullish 🚀🚀🚀
0 · Reply
Earth4thewin
Earth4thewin Jun. 6 at 12:23 AM
$ZVSA is this supposed to get delisted, if so when ?
2 · Reply
Chucky91
Chucky91 Jun. 5 at 1:05 PM
$ZVSA we need some volume here and this thing goes Sky rocket $MULN $MLGO
0 · Reply
max315
max315 Jun. 5 at 12:46 PM
$ZVSA perk - perhaps off of $RVYL so careful of p/d
0 · Reply
TwongStocks
TwongStocks Jun. 4 at 8:55 PM
$CTXR Looks like CTXR has a battle buddy with the NASDAQ appeal. $ZVSA. They received a delist notice on Mar 27, a couple days before CTXR. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001859007/000164117225013038/form8-k.htm ZVSA went 30 days below $1 but is not eligible for any compliance periods, just like CTXR. If both companies end up going through with an appeal hearing, it's possible we find out ZVSA's outcome before CTXR's. ZVSA may provide some sort of expectation for CTXR, if Lenny decides to roll the dice.
2 · Reply
ISWINGER
ISWINGER Jun. 3 at 3:25 PM
$ZVSA I’m tailing you again brother
1 · Reply
Nizou
Nizou Jun. 2 at 8:56 PM
$ZVSA 🚀🚀🚀🚀🚀
0 · Reply
petertradebull
petertradebull Jun. 2 at 5:14 PM
$ZVSA bullish 🚀🚀🚀
0 · Reply